Hutch News

Hutch News

Stories tagged 'clinical trials'

Experimental herpes drug more effective than standard treatment

Pritelivir reduces viral shedding and lesions better than valacyclovir, study shows

Dec. 20, 2016 | By Mary Engel / Fred Hutch News Service

The results of the phase 2, randomized, double-blind trial published today in JAMA showed that when people with genital herpes took a daily oral dose of pritelivir, they reduced their rate of viral shedding by half compared to when they took valacyclovir. They also had fewer genital sores and less pain.

View story >


Quest for an HIV vaccine

Community trust is key as researchers start a new trial across 15 sites in South Africa

Nov. 29, 2016 | By Mary Engel / Fred Hutch News Service

Dr. Linda-Gail Bekker, deputy director of the Desmond Tutu HIV Centre at the University of Cape Town and a member of the Fred Hutch-based HIV Vaccine Trials Network, works closely with the communities most affected by HIV to end the epidemic. She is co-chairing a just-launched clinical trial in South Africa that could lead to the first licensed HIV vaccine.

View story >


Hutch News

Nov. 21, 2016

Stories include: world-renowned oncologist recruited to Fred Hutch, lymphoma patients in remission after experimental immunotherapy and more.

View story >


Empowering ‘millions of women’ against HIV

AMP study in sub-Saharan Africa tests an antibody infusion that could put protection in women’s hands

Oct. 21, 2016 | By Mary Engel / Fred Hutch News Service

The AMP study in sub-Saharan Africa will test whether an antibody infusion protects women against HIV. If it does, the finding will have particular significance for an epidemic that hits women on that continent especially hard and for which they have few prevention options.

View story >


Replenishing immune cells after remission

New approach, not yet tested in humans, aims to restore immune-powering B cells in cancer patients following successful CAR T-cell therapy

Oct. 17, 2016 | By Bill Briggs / Fred Hutch News Service

Scientists at Fred Hutch, Seattle Children’s Research Institute, and Technical University of Munich showed that activating a “kill switch” can turn off CAR T cells after doctors deem a cancer defeated, allowing normal B cells to again flourish.

View story >


HIV prevention gains bring hope — and challenges

Injectable PrEP and other options are in the pipeline, and that makes clinical trials more complicated

Oct. 14, 2016 | By Mary Engel / Fred Hutch News Service

An injectable form of PrEP and other options are in the pipeline as the HIV field enters a new era of prevention. But such advances, as welcome as they are, come with a twist: They complicate the task of designing the clinical trials needed to test additional tools. Fred Hutch's Dr. Deborah Donnell explains.

View story >



(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks

GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.